The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 2 ( April-June, 2022 ) > List of Articles

Original Article

Syndrome Z: Its Response to CPAP Therapy

Ajay Babu, Ankit Pandey, Archana Baburao, Huliraj Narayanswamy

Keywords : Apnea, Blood pressure, Continuous positive airway pressure, Insulin resistance, Metabolic syndrome, Obstructive sleep

Citation Information : Babu A, Pandey A, Baburao A, Narayanswamy H. Syndrome Z: Its Response to CPAP Therapy. Indian J Chest Dis Allied Sci 2022; 64 (2):68-72.

DOI: 10.5005/jp-journals-11007-0012

License: CC BY-NC 4.0

Published Online: 08-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Background: Metabolic syndrome is a constellation of cardiovascular risk factors and its prevalence in obstructive sleep apnea (OSA) is high. The association of OSA and metabolic syndrome is termed as syndrome Z. The effect of continuous positive airway pressure (CPAP) on metabolic syndrome is still controversial. Materials and methods: A total of 145 newly diagnosed patients with OSA were enrolled in this prospective interventional study, who underwent CPAP therapy for 8 weeks. Baseline data including anthropometric variables, blood pressure, fasting glucose levels, insulin resistance and fasting lipid profile of all the study patients were collected before and after the intervention. We determined prevalence of metabolic syndrome in OSA and the effect of CPAP on the components of metabolic syndrome was determined. Results: One hundred-and-six (73.1%) patients were found to have metabolic syndrome. Eighty-four patients were compliant with CPAP therapy. There was statistically significant reduction in glucose systolic (5.5 mm Hg, p = 0.001) and diastolic blood pressure (3.5 mm Hg, p = 0.002), fasting (4.2 mg/dL, p = 0.02), homeostasis model assessment insulin resistance (1.4, p = 0.04) and triglycerides (17.3 mg/dL, p = 0.008) after CPAP therapy. There was modest reversal of metabolic syndrome manifestations in 22 of 84 patients (26.2%) after CPAP therapy. In the CPAP complaint group, a significant reduction in dyslipidemia (p = 0.04) was noted compared to non-compliant group. Conclusion: In patients with syndrome Z, 8 weeks of CPAP therapy was associated with reduction in both systolic and diastolic blood pressure, insulin resistance and triglycerides and modest reversal of metabolic syndrome manifestations.

  1. Coughlin SR, Mawdsley L, Mugarza JA, et al. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004;25(9):735–741. DOI: 10.1016/j.ehj.2004.02.021.
  2. Agrawal S, Sharma SK, Sreenivas V, et al. Prevalence of metabolic syndrome in a north Indian hospital-based population with obstructive sleep apnoea. Indian J Med Res 2011;134(5):639–644. DOI: 10.4103/0971-5916.90988.
  3. Douglas NJ, Polo O. Pathogenesis of sleep apnea/hypopnea syndrome. Lancet 1994;344(8923):653–655. DOI: 10.1016/s0140-6736(94)92088-5.
  4. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163(1):19–25. DOI: 10.1164/ajrccm.163.1.2001008.
  5. Sharma SK, Reddy EV, Sharma A, et al. Prevalence and risk factors of syndrome Z in urban Indians. Sleep Med 2010;11(6):562–568. DOI: 10.1016/j.sleep.2010.02.008.
  6. Soin D, Kumar PA, Chahal J, et al. Evaluation of obstructive sleep apnea in metabolic syndrome. J Family Med Prim Care 2019;8(5):1580–1586. DOI: 10.4103/jfmpc.jfmpc_175_19.
  7. Coughlin SR, Mawdsley L, Mugarza JA, et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007;29(4):720–727. DOI: 10.1183/09031936.00043306.
  8. Campos-Rodriguez F, Grilo-Reina A, Perez-Ronchel J, et al. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. Chest 2006;129(6):1459–1467. DOI: 10.1378/chest.129.6.1459.
  9. Harsch IA, Schahin SP, Redespiel-Tr.ger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004;169(2):156–162. DOI: 10.1164/rccm.200302-206OC.
  10. Jean-Louis G, Zizi F, Clark LT, et al. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med 2008;4(3):261–272. PMCID: PMC2546461.
  11. He J, Kryger MH, Zorick FJ, et al. Mortality and apnea index in obstructive sleep apnea: experience in 385 male patients. Chest 1988; 94(1):9–14. PMID: 3289839.
  12. Mota PC, Drummond M, Winck JC, et al. APAP impact on metabolic syndrome in obstructive sleep apnea patients. Sleep Breath 2011;15(4):665–672. DOI: 10.1007/s11325-010-0417-5.
  13. David Gozal Leila Kheirandish-Gozal. Cardiovascular morbidity in obstructive sleep apnea oxidative stress, inflammation, and much more. Am J Respir Crit Care Med 2008;177(4):369–375. DOI: 10.1164/rccm.200608-1190PP.
  14. Dorkova Z, Petrasova D, Molcanyiova A, et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008;134:686–692. DOI: 10.1378/chest.08-0556.
  15. Hoyos CM, Killick R, Yee BJ, et al. Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnea: a randomized sham-controlled study. Thorax 2012;67:1081–1089. DOI: 10.1136/thoraxjnl-2011-201420.
  16. Baburao A, Souza GD. Insulin resistance in moderate to severe obstructive sleep apnea in nondiabetics and its response to continuous positive airway pressure treatment. North Am J Med Sci 2014;6(10):500–504. DOI: 10.4103/1947-2714.143280.
  17. Saarelainen S, Lahtela J, Kallonen E. Effect of nasal CPAP treatment on insulin sensitivity and plasma leptin. J Sleep Res 1997;6(2):146–7. DOI: 10.1046/j.1365-2869.1997.00034.x.
  18. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:3015–21. DOI: 10.1001/jama.284.23.3015. DOI: 10.1016/j.jaci.2005.02.023.
  19. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115(5):911–919. DOI: 10.1016/j.jaci.2005.02.023.
  20. Alam I, Lewis K, Stephens JW, et al. Obesity, metabolic syndrome and sleep apnoea: all proinflammatory states. Obes Rev 2006;8(2):119–127. DOI: 10.1111/j.1467-789X.2006.00269.x. DOI: 10.1016/0140-6736(90) 90944-z.
  21. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context. Lancet 1990;335(8693):827–838. DOI: 10.1016/0140-6736(90)90944-z.
  22. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278. DOI: 10.1016/S0140-6736(05)67394-1.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.